What can chronic arthritis pain teach about developing new analgesic drugs?
1 Center for Drug Evaluation & Research (CDER), FDA, Rockville, Maryland, USA
2 National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland, USA
Arthritis Res Ther 2004, 6:279-281 doi:10.1186/ar1450Published: 15 October 2004
Chronic pain remains an important public health need with greater impact on the US economy than most other chronic conditions. Current pain management is largely limited to opioids and non-steroidal anti-inflammatory drugs, indicating a gap in the translation of new knowledge to the development of improved pain treatments. Strategies suggested include the re-evaluation of current drug screening methods, a recognition that molecular-genetic events occurring acutely contribute to the development of pain chronicity, the validation of analgesic targets in the intended patient population, consideration of the unique genetic profile that varies between individuals, and the introduction of individual response measures to improve the capture of outcomes in clinical trials.